Marziyeh Etesami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marziyeh Etesami has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Amir Sadeghi
Shahid Beheshti University of Medical Sciences
1 shared publication- Amirreza Hooshmand
Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences & Technology, Tehran Medical Sciences, Islamic Azad University, Tehran 1916893813, Iran
1 shared publication - Ehsan Keramati
Department of Biology ET.C., Islamic Azad University Tehran Iran
1 shared publication Ehsan Nazemalhosseini Mojarad
Shahid Beheshti University of Medical Sciences
1 shared publication- Ehsan Nazemalhosseini-Mojarad
Gastroenterology and Liver Diseases Research center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Faranak Jamshidian
Department of Biology ET.C., Islamic Azad University Tehran Iran
1 shared publication
Latest Publications
- Open Access
- 2 July 2026
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 28, 1-64
Beyond the stomach: Exploring the role of Helicobacter pylori in pushing precancerous lesions to colorectal cancer and the therapeutic potential of probiotics
Colorectal cancer (CRC), a major global health burden, is the second leading cause of cancer deaths. This review examines the link between Helicobacter pylori infection and CRC, highlighting its role beyond gastric pathology. Affecting over half the world’s population, H. pylori is associated with increased CRC risk through direct and indirect mechanisms. Direct pathways include toxins like CagA and VacA, which drive inflammation, and hypergastrinaemia, which promotes colorectal cell proliferation. Indirectly, H. pylori induces immune dysregulation, shifts to immune-evasive coccoid forms, survives intracellularly, releases oncogenic vesicles, disrupts autophagy, alters non-coding RNAs by dysregulating their expression profiles and contributes to gut microbiota dysbiosis. Additionally, we discuss the potential of probiotic interventions to counteract H. pylori ’s pathogenic effects by restoring gut microbial balance, reducing inflammation and modulating immunity by regulating cytokine and T-cell profiles. Future research should translate these molecular insights into clinical applications, including evaluating whether H. pylori eradication reduces CRC risk in high-risk populations and assessing the preventive potential of specific probiotic strains in controlled human trials.
- 2 July 2026
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 28, 1-64
Open AccessBeyond the stomach: Exploring the role of Helicobacter pylori in pushing precancerous lesions to colorectal cancer and the therapeutic potential of probiotics
Colorectal cancer (CRC), a major global health burden, is the second leading cause of cancer deaths. This review examines the link between Helicobacter pylori infection and CRC, highlighting its role beyond gastric pathology. Affecting over half the world’s population, H. pylori is associated with increased CRC risk through direct and indirect mechanisms. Direct pathways include toxins like CagA and VacA, which drive inflammation, and hypergastrinaemia, which promotes colorectal cell proliferation. Indirectly, H. pylori induces immune dysregulation, shifts to immune-evasive coccoid forms, survives intracellularly, releases oncogenic vesicles, disrupts autophagy, alters non-coding RNAs by dysregulating their expression profiles and contributes to gut microbiota dysbiosis. Additionally, we discuss the potential of probiotic interventions to counteract H. pylori ’s pathogenic effects by restoring gut microbial balance, reducing inflammation and modulating immunity by regulating cytokine and T-cell profiles. Future research should translate these molecular insights into clinical applications, including evaluating whether H. pylori eradication reduces CRC risk in high-risk populations and assessing the preventive potential of specific probiotic strains in controlled human trials.
- Open Access
- 3 June 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Investigating the expression of CTLA-4 and CD28 genes as immune regulators in patients with colorectal polyps
- 3 June 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessInvestigating the expression of CTLA-4 and CD28 genes as immune regulators in patients with colorectal polyps
- Open Access
- 1 May 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (5) , e70552
Identification of Critical miRNAs miR ‐4652 and miR ‐1304 as Novel Diagnostic Markers for Oral Squamous Cell Carcinoma
Background: Oral squamous cell carcinoma (OSCC) is marked by frequent recurrence rates and an unclear etiology, underscoring the critical need for early detection to improve therapeutic outcomes and reduce healthcare costs. MicroRNAs (miRNAs) have emerged as key regulators of oral carcinogenesis by modulating gene expression at the posttranscriptional level and influencing various aspects of cellular physiology. Objective: This study aimed to comprehensively evaluate the prognostic significance of miR‐1304 and miR‐4652 expression levels in patients with OSCC, and to explore their potential as predictive biomarkers for disease progression and patient survival. Methods: TargetScan was used to predict potential gene interactions of the microRNAs. Subsequently, the expression levels of C‐Myc and the microRNAs miR‐1304‐3p and miR‐4652‐5p were evaluated in 30 pairs of OSCC and adjacent normal tissue samples. qRT‐PCR analyses were performed to compare the expression of these molecules between tumor and normal tissues. Additionally, receiver operating characteristic (ROC) curves were generated to assess the potential diagnostic value of these microRNAs in OSCC. Result: The expression levels of miR‐1304, miR‐4652, and C‐Myc were significantly higher in OSCC tissues compared to their matched adjacent non‐tumor tissues ( p < 0.0001). Notably, high C‐Myc expression was significantly correlated with both tumor grade ( p = 0.003) and tumor stage ( p = 0.005). ROC curve analysis demonstrated that the areas under the curve (AUCs) for C‐Myc, hsa‐miR‐1304, and hsa‐miR‐4652 were 0.99, 0.99, and 0.95, respectively ( p < 0.0001), indicating strong diagnostic potential. Conclusion: These findings suggest that the upregulation of miR‐1304 and miR‐4652 could be used as biomarkers in OSCC. However, more studies with large samples are necessary.
- 1 May 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (5) , e70552
Open AccessIdentification of Critical miRNAs miR ‐4652 and miR ‐1304 as Novel Diagnostic Markers for Oral Squamous Cell Carcinoma
Background: Oral squamous cell carcinoma (OSCC) is marked by frequent recurrence rates and an unclear etiology, underscoring the critical need for early detection to improve therapeutic outcomes and reduce healthcare costs. MicroRNAs (miRNAs) have emerged as key regulators of oral carcinogenesis by modulating gene expression at the posttranscriptional level and influencing various aspects of cellular physiology. Objective: This study aimed to comprehensively evaluate the prognostic significance of miR‐1304 and miR‐4652 expression levels in patients with OSCC, and to explore their potential as predictive biomarkers for disease progression and patient survival. Methods: TargetScan was used to predict potential gene interactions of the microRNAs. Subsequently, the expression levels of C‐Myc and the microRNAs miR‐1304‐3p and miR‐4652‐5p were evaluated in 30 pairs of OSCC and adjacent normal tissue samples. qRT‐PCR analyses were performed to compare the expression of these molecules between tumor and normal tissues. Additionally, receiver operating characteristic (ROC) curves were generated to assess the potential diagnostic value of these microRNAs in OSCC. Result: The expression levels of miR‐1304, miR‐4652, and C‐Myc were significantly higher in OSCC tissues compared to their matched adjacent non‐tumor tissues ( p < 0.0001). Notably, high C‐Myc expression was significantly correlated with both tumor grade ( p = 0.003) and tumor stage ( p = 0.005). ROC curve analysis demonstrated that the areas under the curve (AUCs) for C‐Myc, hsa‐miR‐1304, and hsa‐miR‐4652 were 0.99, 0.99, and 0.95, respectively ( p < 0.0001), indicating strong diagnostic potential. Conclusion: These findings suggest that the upregulation of miR‐1304 and miR‐4652 could be used as biomarkers in OSCC. However, more studies with large samples are necessary.